The unique ability of dendritic cells to pick up antigens and to activate naive and memory CD4 + and CD8 + T cells raised the possibility of using them to trigger a specific anti-tumor immunity. If numerous studies have shown a major interest in dendritic cell-based vaccines for cancer immunotherapy in animal models, only a few have been carried out in human cancers. In this review, we describe recent findings in the biology of dendritic cells that are important to generate anti-tumor cytotoxic T cells in vitro and we also detail clinical studies reporting the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens.
Introduction
Despite progress in chemotherapy regimens, several malignancies remain incurable by conventional therapies. It is thus necessary to develop alternative strategies, in particular antitumor immunotherapy. Dendritic cells (DC) play a crucial role in the initiation of primary immune response and are therefore probably the best adjuvant for anti-tumor immunity. However, their very low frequency in vivo has limited research in this field. The possibility of obtaining large numbers of DC in vitro has boosted the understanding of their ontogeny and functions. In this paper, we will briefly review the main recent features of DC characteristics that are important for cancer vaccination and discuss the various strategies to vaccinate cancer patients with DC.
Dendritic cells: phenotype and ontogeny
DC constitute a heterogeneous leukocyte population defined by morphologic, phenotypic and functional criteria which distinguish them from monocytes (MO) and macrophages (M⌽). 1 Although there is evidence that a lymphoid precursor can generate DC, T, B and NK cells, 2, 3 we will focus only on myeloid lineage-derived DC which are used both in vitro and in vivo to enhance specific immune response. Originally, DC were characterized by the presence of veils, polarized lamellipodia and long spiny processes that were continually being extended and retracted thus allowing them to be highly motile. 4 As illustrated in Figure 1 , three major DC populations have been identified in vivo: Langerhans cells (LC), interstitial DC and activated mature DC. LC are present in skin epidermis and mucosae and express CD1a, the cutaneous associated antigen (CLA), E-cadherin and the Lag antigen associated with the presence of Birbeck granules. [5] [6] [7] CD1a + interstitial DC are found in various organs especially liver, kidney and heart. LC and interstitial DC pick up antigens (Ag) in peripheral tissues and migrate to lymphoid organs through lymphatic vessels in response to inflammatory stimuli. 8 Activated mature DC, which express CD1a and CD83 antigens, represent the latter stage of LC and interstitial DC maturation. According to their high expression of MHC class I, MHC class II and costimulatory molecules, they present, efficiently, Ag-derived peptides to CD4
+ and CD8 + T lymphocytes in lymph node T cell areas ( Figure 1 ). Recently, another subset of DC was identified on the basis of their high expression of the interleukin-3 receptor alpha chain (IL-3R␣ hi ). These cells are able to migrate to lymphoid organs without any prior activation by inflammatory stimuli. 9 The possibility of generating DC in vitro has helped to understand their ontogeny and to further characterize their phenotype. As illustrated in Figure 2 , all DC subsets originate from bone marrow CD34
+ hematopoietic precursor cells following two overlapping pathways. [10] [11] [12] Granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor ␣ (TNF␣) are the two main cytokines necessary for DC maturation. 13 Stem cell factor (SCF) and Flt3 ligand (Flt3L) enhance the yield of DC generated in vitro from CD34 + cells, 14 and Flt3L-treated mice show a great increase in the number of mature DC. 15 The differentiation of CD34 + cells into LC requires, in addition, transforming growth factor ␤1 (TGF␤1) since TGF␤1 −/− knockout mice are completely devoid of LC. 16 Moreover, TGF␤1 cooperate with Flt3L for the development of CD1a + Lag + LC in vitro. 17 DC can also be generated from peripheral blood CD14
+ MO, at least in vitro. [18] [19] [20] In the presence of macrophage colony-stimulating factor (M-CSF), MO are induced to differentiate into CD14 + M⌽. However, in the presence of GM-CSF and interleukin-4 (IL-4) or interleukin-13 (IL-13), [21] [22] [23] 
CD83
+ mature DC) in the presence of TNF␣ 27, 28 or in response to CD40 ligand (CD40L) stimulation 29, 30 which mimics interaction with T lymphocytes in T cell areas of lymphoid organs. Interestingly, the phenotype of these differentiated cells can be reverted since even fully mature M⌽ can be induced into CD1a +
− immature DC in the presence of IL-4, and vice versa, immature CD1a +
− DC, unlike mature CD1a + CD83 + DC, can acquire a M⌽ phenotype when GM-CSF and IL-4 are replaced by M-CSF. 31 The phenotype of these various DC populations is now better known (Table 1) . DC are defined as lineage-negative cells, ie they do not express classical T cell, B cell, NK cell and monocyte (especially CD14) markers. 1, 32, 33 The usual DC markers are: CD1a which is expressed by LC, MO-derived DC and lymph node DC but not by blood DC and which is involved in the presentation of lipid and glycolipid Ag to T Review K Tarte and B Klein 654
Figure 1
Immature DC are localized in peripheral tissues and migrate to lymphoid organs where they activate T lymphocytes. cells; [33] [34] [35] [36] CD83 which is present on some rare circulating blood DC 34 and which is induced during DC maturation (cultured blood DC, mature MO-derived DC, lymph node DC); 37 CMRF-44 which is less specific than CD83 and is also expressed by a subset of blood DC and LC. CD83 and CMRF-44 have unknown functions but they are interesting for DC positive selection.
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Dendritic cell functions in vitro and in vivo
Again, due to the possibility of producing DC in vitro, their maturation and function have been extensively characterized. Immature DC are able to capture and process Ag extensively in the periphery. They can internalize soluble Ag by macropinocytosis, 39 ie uptake of large vesicules (0.5-3 m), as well as by endocytosis of small vesicules 40 by at least two types of receptors for Ag uptake: Fc receptor and mannose receptor. CD32 (Fc␥RII), CD64 (Fc␥RI) and mannose receptor are downregulated during DC maturation in vitro 39, 41, 42 ( Figure 3 ). LC and interstitial DC are phagocytic but to a lesser extent than M⌽ and this capacity is lost during DC maturation. 42, 43 Immature DC are also able to internalize apoptotic cells by binding them through ␣ v ␤ 5 , ␣ v ␤ 3 and CD36 adhesion molecules 44 ( Figure 3 ). In particular, ␣ v ␤ 5 is absent on MO/M⌽ and this could explain why these cells are unable to present Ag derived from apoptotic cells, even if they internalize apoptotic cells very efficiently. Ag capture is optimal for immature dendritic cells generated from peripheral blood MO after 5-7 days of culturing with GM-CSF and IL-4. When DC are induced to mature in vitro, in particular in the presence of TNF␣ or CD40L stimulation, they lose their ability to internalize soluble Ag and apoptotic cells 39, 44 ( Figure 3 ). Together with Ag uptake, Ag processing is also modulated during DC maturation. Ag are concentrated in MHC II compartments in immature cells and, after treatment with TNF␣, these intracellular vesicules disappear and surface MHC II expression is upregulated. 39, 45 It is now well documented that immature DC can process exogenous soluble proteins captured by macropinocytosis for MHC class I presentation. [46] [47] [48] This could explain the cross-priming phenomenon: in vivo, MHC I-restricted tumor Ag are presented mainly, if not exclusively, by professional APC (mainly DC) that have taken up Ag released by dying tumor cells, rather than by the tumor cells themselves. 49 This is of major importance for vaccination strategies for cancer patients. The method of Ag capture influences its presentation. Endocytosis via mannose receptor seems more efficient for MHC class I presentation than endocytosis via Fc recep- tor. 50 In addition, engulfed apoptotic cells generate MHC class I-restricted peptides. 44, 51, 52 After Ag uptake and processing, DC leave peripheral tissues and migrate to lymphoid organs in order to present Ag to T lymphocytes ( Figure 1) . 8 This migration could be explained by the switch in chemokine receptor expression induced through DC maturation. 53, 54 Immature DC express CCR1 and CCR5, which are the receptors for some inflammatory chemo-
Figure 3
DC differentiation and maturation in vitro: modulation of molecules involved in Ag uptake, Ag presentation and DC migration.
kines, namely macrophage inflammatory protein (MIP)-1␣, MIP-1␤ and RANTES. Induction of DC maturation by CD40 ligand (CD40L), TNF␣ or LPS results in a rapid downregulation of these receptors, allowing DC to leave inflamed tissues. It also results in the slower induction of CCR7, which is the receptor for MIP-3␤/EBI1 ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC), two chemokines constitutively produced in lymphoid organs. In the lymph nodes, DC form clusters with T lymphocytes through various adhesion molecules, in particular CD54 (ICAM-1), CD102 (ICAM-3) and CD58 (LFA-3), that are highly expressed by activated DC. 55 The DC/T cell interaction is stabilized by the specific ligation of the T cell receptor (TCR) by the MHC-peptide complex, which delivers the first activation signal to T lymphocytes. A second costimulatory signal is absolutely necessary to avoid T cell anergy and allow T cell proliferation. This signal is mediated in part by the interaction of CD80 (B7-1) and CD86 (B7-2), both of which present on DC, with T cell CD28. Immature resting DC express few CD80 and CD86 but these molecules are rapidly induced upon differentiation/ activation, 56 especially after contact with T lymphocytes which allows CD40-CD40L interaction.
30 CD40 is constitutively expressed by DC and is upregulated by several cytokines such as GM-CSF and TNF␣.
57 CD40 stimulation upregulates CD80-CD86 expression on DC 57 and induces them to produce p75 interleukin-12 (IL-12), 29, 58 which plays the key role in the emergence of Th1 cellular response. Recent studies show that in vivo DC initially activate CD4 + T cells ( Figure  4 ). Activated CD4 + T lymphocytes become CD40L + and deliver, in turn, a stimulation signal to CD40 + DC. These 'conditioned' DC are then able to prime Ag-specific CD8 + T cells. This two-step model of T cell activation explains why CD4 + help is necessary to get cytotoxic T lymphocytes. However, CD4
+ help can be replaced by anti-CD40 antibodies which might be interesting for developing anti-tumor cytotoxic T lymphocytes (CTL) in vitro using DC pulsed with MHC Irestricted peptides. [59] [60] [61] Other costimulatory molecules are likely to be important for T cell activation. Among them, OX40 ligand (OX40 L) is inducible by CD40 stimulation on DC 62 and it might play a major role in T cell priming. First, OX40 L engagement increases DC maturation and expression of CD80 and CD86. 62 Secondly, OX40 cross-linking on CD4 + activated T cells costimulates their proliferation and cytokine production. Cross-talk of DC with CD4 + and CD8 + T cells. Role of CD40 and other costimulatory molecules.
costimulatory molecules, and production of IL-12 by mature DC, make them very potent professional APC.
Generation of human DC for vaccination strategies
According to their ontogeny, DC from three sources can be used to vaccinate patients with cancer. DC can be purified from peripheral blood. After a short in vitro culture, their low density allows enrichment by using centrifugation on metrizamide or Nycodenz gradients, 32, 64 or elutriation. 65 Blood DC can also be purified after removal of other defined T, B, NK and MO populations by using antibodies and magnetic beads or a cell-sorter, on the basis of their HLA DR ++ and lineage − phenotype 35 or according to their expression of CD83 or CMRF-44 molecules. 38 However, the very low frequency of DC in accessible body samples, especially blood, limits the use of these DC for vaccination protocols.
It is now far easier to generate DC in vitro. According to the knowledge of DC ontogeny (Figure 2 ), two major strategies are used. The first is based on the ability of CD34 + progenitors isolated from bone marrow, 66, 67 peripheral blood 68 or neonatal cord blood 11 to differentiate in vitro within 14 days into mature CD1a + CD83 + HLA DR ++ DC in the presence of GM-CSF and TNF␣. The addition of IL-4 could enhance DC purity but not DC yield, unlike SCF and Flt3L which synergistically allow the obtention of large numbers of DC. One of the advantages of this methodology is the high rate of cell proliferation which occurs during the first days of cell culture and allows gene transfer with retrovirus. However, there are several limitations: these cell populations contain only 50% of DC, several cytokines are required and it is difficult to clearly separate the phase of Ag capture and processing from the phase of Ag presentation, especially since TNF␣ needs to be added at the beginning of the culture.
The second major strategy uses purified peripheral blood CD14 + MO or adherent mononuclear cells and makes it possible to obtain a cell population containing 90% of immature CD1a + CD83 − DC in the presence of only two cytokines (GM-CSF and IL-4 or IL-13). [18] [19] [20] 69 As illustrated in Figure 3 and discussed above, this methodology makes it possible to separate easily the phase of Ag capture and processing and the phase of Ag presentation since TNF␣ or other maturating stimuli can be added in the course of the culture. 27, 28 Thus, tumor Ag requiring internalization and processing (soluble proteins, RNA, apoptotic cells) must be added to immature CD1a
− DC (5-7 days of culture with GM-CSF and IL-4). Conversely, defined 9-mer synthetic peptides which bind directly to MHC molecules without processing must be added to mature DC, which express high amounts of MHC class I and II after 2 additional days of culture with TNF␣, CD40L or monocyte-conditioned medium. Noteworthy, the use of apheresis cells collected in very large amounts during hematopoietic precursor mobilization with growth factors greatly enhances the DC yield. 19, 69 This is explained by the proliferation and differentiation in vitro of some non-CD34
+ adherent DC precursors that are not present in normal non-mobilized peripheral blood. This proliferation can be increased by adding IL-3 and TNF␣, 69 indicating that it might involve some IL-3R␣ hi cells. To date, apheresis samples are collected after treatment with G-CSF or GM-CSF. However, it would be interesting to study the effect of other mobilization reagents, particulary SCF and Flt3L, on DC precursor mobilization. 14 The reason why the majority of in vitro or in vivo studies use these MO-derived DC to generate anti-tumor immunity is that they are easy to obtain.
For immunization protocols, it is important to minimize the presence of xenogenic or allogenic Ag, especially coming from fetal calf serum, which may be immunodominant, although these Ag could be interesting adjuvants for in vivo immunization. In addition, serum contains proteases that may alter the antigenicity of MHC I-restricted peptides added in vitro on DC preparations. 70 Finally, serum contains numerous proteins, particularly antibodies, which may interfere with the method of Ag capture and processing. This has been shown for human natural anti-Gal␣(1,3)Gal antibodies that crossreact with MUC-1 peptides and therefore drive an endocytosis of mannose receptor-targeted MUC-1 peptides through Fc and complement receptors. This induces a MUC-1 presentation through MHC II molecules and favors antibody production. 50 On the other hand, when these mannose receptor-targeted MUC-1 peptides are endocytosed through mannose receptor, 17 Monocyte-conditioned medium 23, 73 or TNF␣ + prostaglandin E2 (PGE2) 74, 77 can be added, after 5-7 days of culture, to trigger the maturation of MO-derived DC obtained with GM-CSF and IL-4. This will enhance their ability to activate T lymphocytes and will induce the expression of appropriate chemokine receptors, especially CCR7, to guide localization of DC into lymphoid organs after DC injection in vivo.
The choice of culture conditions, especially the cytokine combination, will influence DC purity, maturation and functionality, and this is a consideration of prime importance before starting DC-based immunotherapy assays.
Suppression of endogenous DC function in patients with cancer
It has been reported that tumor infiltration by DC is a factor of good prognosis in several cancers. [79] [80] [81] [82] However, there is no evidence that these DC are able to pick up and efficiently present tumor-associated Ag (TAA). In particular, tumor cells produce cytokines that inhibit DC differentiation, recruitment or functions. Interleukin-10 (IL-10), a potent immunosuppressive cytokine, is produced by melanoma, brain neoplasm, B lymphoma, myeloma and several carcinoma tumor cells.
83-88
In vitro, IL-10 prevents the generation of MO-derived DC induced by GM-CSF and IL-4 and favors the development of MO. 89, 90 In vivo, IL-10 production by tumor cells has been shown to prevent DC accumulation and anti-tumor immunity in a murine model. 91 In addition, all immunosuppressive treatments used in cancer, especially high-dose chemotherapy associated with auto-or allograft, could affect DC.
Preclinical studies of anti-tumor vaccination with DC
Several approaches, depending on the TAA added on DC, have been used. They are summed up in Figure 5 . The objective is to obtain professional TAA presenting cells using tumor cells that express TAA but fail to present them, and autologous DC that express no TAA. A number of tumor Ag recognized by CD8
+ CTL have already been identified 92 ( Figure 5a ). These defined Ag can simply be added as 9-11 mer HLA I-restricted peptides to mature DC preparation in the presence of ␤2 microglobulin. [93] [94] [95] [96] [97] However, it has been suggested that the use of longer peptides or complete proteins, 98, 99 which are not directly presented but are endocytosed and processed, is a better way to generate a fully competent DC vaccine since it allows selection by the APC of the optimal 9-mer peptide for presentation. 98 After cloning, these tumor Ag can also be used as cDNA in appropriate vectors to load DC. Transfection of human DC have been reported using adenovirus for MOderived DC 100 and retrovirus for CD34 + -derived DC 101, 102 but, in contrast to murine models, [103] [104] [105] [106] the efficiency of transfected DC to stimulate anti-tumor CTL in vivo has not yet been demonstrated in human. The use of retroviral, unlike adenoviral, transfer could allow stable expression, processing and presentation of TAA epitopes. 101 There are three major restrictions when using defined tumor Ag. Firstly, identification of effective TAA is lacking in a large number of cancers. Secondly, it is now clear that immunotherapy approaches directed against a unique Ag will favor the selection of tumor mutants that have selectively lost the ability to present efficiently the defined Ag. 107 Thirdly, the obtention of Ag-specific CTL in vitro is not a guarantee of the development of a curative immune response in vivo. To bypass these disadvantages, several alternative methodologies using a mix of TAA have been developed. Unfractionated MHC Ipresented peptides can be eluted from tumor cells 108 and loaded on to DC. 109 DC are also able to internalize complete cell lysates 110 or apoptotic cells 44, 51, 52 and to present derived Ag in an HLA I-restricted manner. For these strategies, the major concerns are the need for large numbers of primary samples or tumor cell lines and the risk of autoimmune reaction. As discussed recently, 111 the use of RNA instead of protein could constitute a good alternative since it could be amplified in vitro. In addition, substractive hybridization could allow the enrichment of tumor-specific RNA, thus limiting immune response against self Ag.
110,112,113 Two other methods have been explored. The first one is the fusion of murine tumor cell lines with bone marrow-derived DC ( Figure  5b ). This interesting work leads to the obtention of a hybrid displaying functional properties of DC and expressing tumor Ag. 114, 115 However, cell fusion followed by selection requires pure and proliferating neoplastic cells which is a major technical limitation when applied to human cancers. In this context, the recent demonstration that cell-contact generated by shortterm coculture of DC and tumor cells without cell fusion results in a potent immunogen is particularly relevant. 116 The second method is specific to the human chronic myeloid leukemia (CML) model (Figure 5c ). In this disease, tumor cells can be induced to differentiate, in vitro, in the presence of GM-CSF, IL-4 and TNF␣, into mature DC able to stimulate autologous anti-leukemic CTL. 117 Finally, tumor Ag-presenting DC can be used directly to generate specific CTL in vitro and in vivo or to produce exosomes. These secreting vesicules express MHC I, MHC II and CD86 molecules and are efficient in priming CTL, at least in vivo in murine models. 118 Among all these different methodologies, those which have been successfully used in vitro to obtain human anti-tumor CTL are summarized in Table 2 . These studies are encouraging and they used HLA-restricted peptides, 72, 94, 95, 97, 98, 119 cloned cDNA, 101 cell lysates, 72 irradiated tumor cells 76 or tumor RNA 113 as tumor Ag. The source of DC was either purified DC, MO-derived DC or CD34 + -derived DC. Optimization of the different steps, ie Ag uptake, Ag presentation and coculture protocols is now in process. For example, it has been demonstrated that treatment of MO-derived DC, obtained in serum-free AIM-V medium, with anti-sense oligonucleotides to the mRNA of transporter associated with antigen presentation (TAP) or with MG132 proteasome inhibitor decreases the association of MHC I molecules with endogeneously generated peptides, thus enhancing exogeneously added peptide presentation. 119 Immature MO-derived DC are very interesting since their high endocytic ability allows them to capture tumor proteins and to internalize tumor RNA without any transfection reagent being added. 113 However, it should be emphasized that, to date, the great majority of the studies reporting the in vitro obtention of CTL to human tumor cells were carried out with DC and T cells of healthy individuals. Only five studies have used cells obtained from 
Table 2
In vitro obtention of anti-tumor CTL using DC in human cancers patients. 72, 94, 101, 113, 117 In addition, a CTL activity against autologous tumor cells was reported in only two studies 72, 117 (less than 10 patients in all): one performed on CML patients and one on melanoma patients.
Clinical studies of anti-tumor vaccination with DC
Only five studies concerning the in vivo use of DC in human cancer have been published to date [120] [121] [122] [123] [124] [125] (Table 3) but others have now been started. Three of them report objective clinical responses. The first study was carried out on B cell lymphoma patients using DC purified from peripheral blood by density gradient centrifugation, pulsed with idiotype protein (Id) and reinfused. 124 All lymphoma patients treated developed a cellular response as shown by the proliferation of PBMC in the presence of tumor Id without anti-Id antibody production. Among four patients studied, one had a partial regression of some tumor sites, one underwent a complete tumor regression and, for one patient with equivocal radiographic findings, evaluation of residual disease by PCR showed that bone marrow and blood tumor cells had disappeared. The second study was carried out on patients with advanced melanoma using MO-derived DC pulsed with a mixture of HLA-restricted melanoma peptides or with cell lysates to avoid the selection of TAA − tumor cells. 121 Biological response was evaluated by delayed-type hypersensitivity (DTH) reactivity. Among the 12 patients treated with DC pulsed with A1 and/or A2-restricted peptides, nine showed a DTH reactivity to DC loaded with these peptides. However, a significant DTH reactivity (Ͼ10 mm in diameter) was observed in only five patients with Table 3 In vivo immunization with TAA-pulsed DC in human cancers four of them demonstrating a clinical response to treatment (one complete response (CR), two partial responses (PR) and one minor response (MR)). Among the four patients treated with DC pulsed with tumor cell lysates, two developed DTH reactivity toward the lysate in association with clinical response (one CR and one PR). The two patients with CR were still tumor-free 15 months later. Finally, the third study was carried out on metastatic renal cancer patients using MOderived DC pulsed with KLH and autologous tumor cell lysate. 125 Only two patients completed the treatment and one of them showed a proliferative response of PBMC against cell lysates in association with a regression of tumor mass of 61%. The method of administration and the nature of adjuvants are certainly more important than the absolute number of reinjected DC since as few as 1 to 2 × 10 6 DC are able to mount a specific immune response. On this basis, Nestle et al 121 used a direct intralymphatic injection to minimize DC loss. One may hypothesize that the knowledge of chemokine receptor modulation will help to direct reinjected DC to lymphoid organs. In addition, DC were generated in the presence of xenogenic FCS Ag and KLH neo-Ag to favor an adjuvant T helper cell response. 121 Another important factor which governs the efficiency of DC-based vaccines is the immunological status of treated patients. It must be emphasized that all clinical assays were performed on advanced stage disease. Immunocompetent young patients with minimal residual disease would probably be the best candidates for these approaches. Nevertheless, biological anti-tumor responses were detectable in all studies and DC vaccine seems to be well tolerated with no significant adverse events despite the high rate of autoantibodies reported by Nestle et al 121 (three patients with antiReview K Tarte and B Klein 660 TSH receptor antibodies and one patient with antinuclear antibodies). In patients with multiple myeloma (MM), a late B cell disorder, the monoclonal immunoglobulin should be an interesting tumor Ag since its genes are somatically hypermutated 126 and since it can be purified from serum. Accordingly, one study reports an Id-specific T cell proliferative response after vaccination of only one MM patient with autologous MO-derived DC pulsed with monoclonal component. IgM and IgG anti-Id antibodies were detected without any clinical response. 127 Several other studies are now in progress in this disease.
All these preliminary data are very promising and indicate that DC could be safely used in vivo as immunotherapy adjuvants in a wide variety of cancers even without identified TAA.
